World Lung Cancer Day: Advances in metastatic NSCLC; value of screening for nonsmokers
Click Here to Manage Email Alerts
Today is World Lung Cancer Day.
The observance — held annually on Aug. 1 — is intended to raise awareness about the impact of lung cancer.
In conjunction with World Lung Cancer Day, Healio presents the following important updates in treatment, research and screening.
1. Circulating tumor DNA genotyping before tissue diagnosis of suspected advanced non-small cell lung cancer resulted in significantly shorter median time to treatment compared with standard tissue testing. Read more.
2. The addition of amivantamab-vmjw (Rybrevant, Janssen) to chemotherapy extended PFS among patients with newly diagnosed advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. Read more.
3. Datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) improved PFS compared with standard chemotherapy for patients with locally advanced or metastatic NSCLC who received at least one prior therapy. Read more.
4. More than one-third of adults with previously untreated stage III NSCLC exhibited a pathologic complete response after receiving perioperative nivolumab (Opdivo, Bristol Myers Squibb) plus chemotherapy. Read more.
5. Types and sizes of meals may impact the effectiveness of alectinib (Alecensa, Genentech) for patients with lung cancer. Read more.
6. American Society for Radiation Oncology, in collaboration with European Society for Radiotherapy and Oncology, issued a new guideline on use of definitive local therapy for patients with oligometastatic NSCLC. Read more.
7. Adjuvant osimertinib (Tagrisso, AstraZeneca) conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA NSCLC. Read more.
8. Tumor-treating fields (Novocure) prolonged survival for patients with metastatic NSCLC whose disease progressed on or after platinum therapy. Read more.
9. A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria. The findings highlight the need for more emphasis on early detection of lung cancer, investigators concluded. Read more.
10. MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated NSCLC will respond to subsequent combination therapy with amivantamab plus lazertinib (Leclaza; Yuhan, Janssen). Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts